Dr Naadir Gutta

Clinical Haematologist
Become a Patient

Dr Naadir Gutta is committed to providing his patients with personalised treatment plans, tailored to suit their individual needs. He brings a compassionate, measured approach to his practice to ensure his patients are supported throughout their treatment and beyond.


Dr Naadir Gutta is an experienced clinical haematologist at Icon Cancer Centre Greenslopes and Icon Cancer Centre South Brisbane. He completed his undergraduate medical training in South Africa and then completed his specialist haematology training in Queensland. In addition to his private work, Dr Gutta is Clinical Director of Haematology at Mater Hospital. He is also a fellow of the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA).

Dr Gutta maintains a strong interest in clinical research and education, actively completing research in the treatment of malignant and non-malignant haematological conditions. He is involved in general practitioner and undergraduate medical education, providing educational support and delivering formal lectures at the University of Queensland.

His clinical experience covers a broad range of malignant and non-malignant blood disorders including myeloma, lymphoma, chronic lymphocytic leukaemia, thrombosis and haemostasis. Dr Gutta also has a keen interest in obstetric haematology.

Affiliations & Memberships

  • Australasian Society for Thrombosis and Haemostasis (ASTH)
  • Royal Australasian College of Physicians (RACP)
  • Royal College of Pathologists Australasia (RCPA)

Special Interests

Dr Naadir Gutta accepts referrals for malignant and non-malignant blood disorders, with a special clinical interest in:
  • Haematology
  • Leukaemia
  • Lymphoma
  • Multiple myeloma
  • Obstetric haematology
  • Thrombosis and haemostasis

Icon Locations

Greenslopes View centre
South Brisbane View centre

Visiting Locations

  • Sunnybank Private Hospital


  • Transfusion-related Acute Lung Injury (TRALI): a review of current literature and presentation of reported TRALI cases in Queensland between 1999 – January 2013. Gutta, G. Hodges, M. Kelly, L. Phillips, S.J. Bryant, K. Goodison, G. Mraz, R. Holdsworth & S. Baidya. HAA 2013 Annual Scientific Meeting, 2013.

  • Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin’s lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure. M. Fong, S. Boyle & N. Gutta. BMJ Case Reports CP, 2019; 12.

  • Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Bhurani, L. Admojo, C. Van Der Weyden, R. Twigger, A. Bazargan, H. Quach, A. Zimet, L. Coyle, J. Lindsay, D. Radeski, E. Hawkes, G. Kennedy, I. Irving, N. Gutta, J.Trotman, J. Yeung, L. Dunlop, M. Hua, P. Giri, S. Yuen, S. Panicker, S. Moreton, L. Khoo, A. Scott, D. Kipp, A. McQuillan, C. McCormack, M. Dickinson & H. Prince. Leukemia & Lymphoma, 2020.